These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35475308)

  • 1. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
    Pipe SW; Hermans C; Chitlur M; Carcao M; Castaman G; Davis JA; Ducore J; Dunn AL; Escobar M; Journeycake J; Khan O; Mahlangu J; Meeks SL; Mitha IH; Négrier C; Nowak-Göttl U; Recht M; Chrisentery-Singleton T; Stasyshyn O; Vilchevska KV; Martinez LV; Wang M; Windyga J; Young G; Alexander WA; Bonzo D; Macie C; Mitchell IS; Sauty E; Wilkinson TA; Shapiro AD
    Haemophilia; 2022 Jul; 28(4):548-556. PubMed ID: 35475308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
    Escobar M; Castaman G; Boix SB; Callaghan M; de Moerloose P; Ducore J; Hermans C; Journeycake J; Leissinger C; Luck J; Mahlangu J; Miesbach W; Mitha IH; Négrier C; Quon D; Recht M; Schved JF; Shapiro AD; Sidonio R; Srivastava A; Stasyshyn O; Vilchevska KV; Wang M; Young G; Alexander WA; Al-Sabbagh A; Bonzo D; Macie C; Wilkinson TA; Kessler C
    Haemophilia; 2021 Nov; 27(6):921-931. PubMed ID: 34636112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
    Escobar M; Luck J; Averianov Y; Ducore J; Fernández MFL; Giermasz A; Hart DP; Journeycake J; Kessler C; Leissinger C; Mahlangu J; Martinez LV; Miesbach W; Mitha IH; Quon D; Reding MT; Schved JF; Stasyshyn O; Vilchevska KV; Wang M; Windyga J; Alexander WA; Al-Sabbagh A; Bonzo D; Mitchell IS; Wilkinson TA; Hermans C
    Haemophilia; 2021 Nov; 27(6):911-920. PubMed ID: 34614267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
    Pipe SW; Dunn AL; Young G
    Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
    Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
    Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series.
    Youkhana K; Batsuli G; Acharya S; Khan O; Tran DQ; Dvorak A; Recht M; Young G; Sidonio R; Abajas Y
    Haemophilia; 2024 Sep; ():. PubMed ID: 39297369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice.
    Ciolek AM; Arnall J; Moore DC; Palkimas S; Der-Nigoghossian J; Dane K
    Ann Pharmacother; 2022 Jul; 56(7):831-838. PubMed ID: 34595941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.
    Alexander WA; Jensen I; Hathway J; Srivastava K; Cyr P; Sidonio RF; Batt K
    J Manag Care Spec Pharm; 2022 May; 28(5):518-527. PubMed ID: 35343812
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
    Biron-Andreani C; Schved JF
    Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of eptacog alfa in nonhaemophiliac conditions.
    Mallarkey G; Brighton T; Thomson A; Kaye K; Seale P; Gazarian M
    Drugs; 2008; 68(12):1665-89. PubMed ID: 18681490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(8):1161-77. PubMed ID: 15907148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
    Watson N; Al-Samkari H
    Drugs Today (Barc); 2022 Mar; 58(3):105-116. PubMed ID: 35274630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
    Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
    Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.